

PAN1 Study Trial Report

PAN1: A randomised phase II study evaluating potential predictive biomarkers in the treatment of locally advanced and metastatic pancreatic cancer.

Overview: To prospectively evaluate hENT1 as a predictive marker of benefit from gemcitabine treatment in locally advanced and metastatic pancreatic cancer.

Study Chair: Dr Yu Jo Chua, Medical Oncologist, Canberra Hospital

Open Date: 22nd July 2011

Accrual: 8 / 80 patients

Trial Management Committee Members:

Yu Jo Chua	Canberra Hospital	ACT
Andrew Biankin	Garvan Institute of Medical Research	NSW
Chris Karapetis	Flinders Medical Centre	SA
Craig Underhill	Border Medical Oncology	VIC
Louise Nott	Royal Hobart	TAZ
David Goldstein	Prince of Wales Hospital	NSW
Michelle Cronk	Nambour Hospital	QLD
George Laking	Auckland Hospital	NZ
Val GebSKI	NHMRC Clinical Trials Centre	NSW
Katrin Sjoquist	NHMRC Clinical Trials Centre	NSW
Nicole Wong	NHMRC Clinical Trials Centre	NSW
Fabyolla El-Tahche	NHMRC Clinical Trials Centre	NSW

Study Progress:

- The PAN1 study is coordinated by the NHMRC Clinical Trials Centre.
- Received funding from the Avner Nahmani Pancreatic Cancer Research Fund.
- 20 sites are planned with 12 sites activated to-date.
- The NHMRC Clinical Trials Centre is currently reviewing new potential sites for the study and performing feasibility assessments to determine their suitability for PAN1. The NHMRC Clinical Trials Centre will work with the new sites as soon as they are ready to join the study. Four (4) new sites have been approved and are being prepared for start-up by NHMRC CTC.
- PAN1 'Trials In Progress' Abstract was presented at ASCO 2012.
- PAN1 study was presented at the AGITG Annual Scientific Meeting in September.
- The latest PAN1 Trial Management Committee (TMC) meeting occurred on 27 November 2012. The next TMC meeting is scheduled for February 2013.
- External review committee meeting occurred on 15 October 2012 to perform an independent review of the protocol and recruitment strategies.
- Monthly screening logs are collected from all sites for ongoing monitoring of patient screening and review of ongoing recruitment at sites. The PAN1 TMC is providing ongoing guidance and direction in the screening of any potential, eligible patients.
- Eight (8) patients have been randomised onto the PAN1 study to-date. Of the patients considered for the PAN1 study, there have been 62 pancreatic cancer patients screened to-date, with 2 patients currently in screening. Please refer to the table below for more information.

PAN1 Study Trial Report

Site summary:

Site Name	Activation Date	Recruited	Screened
Canberra Hospital	22-Jul-2011	1	11
Tweed Hospital	27-Jul-2011	1	5
Royal Hobart Hospital	28-Jul-2011	1	10
Nambour General Hospital	31-Aug-2011	0	3
Border Medical Oncology	22-Sep-2011	1	4
Geelong Hospital	27-Sep-2011	0	4
Townsville Hospital	27-Sep-2011	0	11
Royal North Shore Hospital	03-Nov-2011	0	1
Port Macquarie Hospital	23-Nov-2011	0	5
Flinders Medical Centre	12-Dec-2011	1	1
Royal Perth Hospital	17-Jan-2012	1	1
Prince of Wales Hospital	29-Jun-2012	2	6
<i>Southern Medical Day Care Centre</i>	<i>In Start-up: HREC Approved</i>		
<i>Bankstown-Lidcombe Hospital</i>	<i>In Start-up: HREC Approved</i>		
<i>Queen Elizabeth Hospital</i>	<i>In Start-up</i>		
<i>Royal Adelaide Hospital</i>	<i>In Start-up</i>		
TOTAL:		8	62

